158 related articles for article (PubMed ID: 30719255)
1. Effect of Co-administration of Bumetanide and Phenobarbital on Seizure Attacks in Temporal Lobe Epilepsy.
Rahmanzadeh R; Mehrabi S; Barati M; Ahmadi M; Golab F; Kazmi S; Joghataei MT; Seifi M; Gholipourmalekabadi M
Basic Clin Neurosci; 2018; 9(6):408-416. PubMed ID: 30719255
[TBL] [Abstract][Full Text] [Related]
2. Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy.
Brandt C; Nozadze M; Heuchert N; Rattka M; Löscher W
J Neurosci; 2010 Jun; 30(25):8602-12. PubMed ID: 20573906
[TBL] [Abstract][Full Text] [Related]
3. Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice.
Hampel P; Römermann K; Gailus B; Johne M; Gericke B; Kaczmarek E; Löscher W
Neuropharmacology; 2021 Mar; 185():108449. PubMed ID: 33450274
[TBL] [Abstract][Full Text] [Related]
4. BDNF modifies hippocampal KCC2 and NKCC1 expression in a temporal lobe epilepsy model.
Eftekhari S; Mehrabi S; Soleimani M; Hassanzadeh G; Shahrokhi A; Mostafavi H; Hayat P; Barati M; Mehdizadeh H; Rahmanzadeh R; Hadjighassem MR; Joghataei MT
Acta Neurobiol Exp (Wars); 2014; 74(3):276-87. PubMed ID: 25231847
[TBL] [Abstract][Full Text] [Related]
5. Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy.
Brandt C; Seja P; Töllner K; Römermann K; Hampel P; Kalesse M; Kipper A; Feit PW; Lykke K; Toft-Bertelsen TL; Paavilainen P; Spoljaric I; Puskarjov M; MacAulay N; Kaila K; Löscher W
Neuropharmacology; 2018 Dec; 143():186-204. PubMed ID: 30248303
[TBL] [Abstract][Full Text] [Related]
6. The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice.
Erker T; Brandt C; Töllner K; Schreppel P; Twele F; Schidlitzki A; Löscher W
Epilepsia; 2016 May; 57(5):698-705. PubMed ID: 26921222
[TBL] [Abstract][Full Text] [Related]
7. A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy.
Gharaylou Z; Tafakhori A; Agah E; Aghamollaii V; Kebriaeezadeh A; Hadjighassem M
CNS Drugs; 2019 Mar; 33(3):283-291. PubMed ID: 30784026
[TBL] [Abstract][Full Text] [Related]
8. Bumetanide is not capable of terminating status epilepticus but enhances phenobarbital efficacy in different rat models.
Töllner K; Brandt C; Erker T; Löscher W
Eur J Pharmacol; 2015 Jan; 746():78-88. PubMed ID: 25445051
[TBL] [Abstract][Full Text] [Related]
9. Hippocampal chloride transporter KCC2 contributes to excitatory GABA dysregulation in the developmental rat model of schizophrenia.
Atefimanash P; Pourhamzeh M; Susanabadi A; Arabi M; Jamali-Raeufy N; Mehrabi S
J Chem Neuroanat; 2021 Dec; 118():102040. PubMed ID: 34695562
[TBL] [Abstract][Full Text] [Related]
10. Deletion of the Na-K-2Cl cotransporter NKCC1 results in a more severe epileptic phenotype in the intrahippocampal kainate mouse model of temporal lobe epilepsy.
Hampel P; Johne M; Gailus B; Vogel A; Schidlitzki A; Gericke B; Töllner K; Theilmann W; Käufer C; Römermann K; Kaila K; Löscher W
Neurobiol Dis; 2021 May; 152():105297. PubMed ID: 33581254
[TBL] [Abstract][Full Text] [Related]
11. Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy.
Eftekhari S; Mehvari Habibabadi J; Najafi Ziarani M; Hashemi Fesharaki SS; Gharakhani M; Mostafavi H; Joghataei MT; Beladimoghadam N; Rahimian E; Hadjighassem MR
Epilepsia; 2013 Jan; 54(1):e9-12. PubMed ID: 23061490
[TBL] [Abstract][Full Text] [Related]
12. Bumetanide enhances phenobarbital efficacy in a neonatal seizure model.
Dzhala VI; Brumback AC; Staley KJ
Ann Neurol; 2008 Feb; 63(2):222-35. PubMed ID: 17918265
[TBL] [Abstract][Full Text] [Related]
13. Depolarizing γ-aminobutyric acid contributes to glutamatergic network rewiring in epilepsy.
Kourdougli N; Pellegrino C; Renko JM; Khirug S; Chazal G; Kukko-Lukjanov TK; Lauri SE; Gaiarsa JL; Zhou L; Peret A; Castrén E; Tuominen RK; Crépel V; Rivera C
Ann Neurol; 2017 Feb; 81(2):251-265. PubMed ID: 28074534
[TBL] [Abstract][Full Text] [Related]
14. Anomalous levels of Cl- transporters cause a decrease of GABAergic inhibition in human peritumoral epileptic cortex.
Conti L; Palma E; Roseti C; Lauro C; Cipriani R; de Groot M; Aronica E; Limatola C
Epilepsia; 2011 Sep; 52(9):1635-44. PubMed ID: 21635237
[TBL] [Abstract][Full Text] [Related]
15. A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia.
Johne M; Käufer C; Römermann K; Gailus B; Gericke B; Löscher W
Epilepsia; 2021 Jun; 62(6):1460-1471. PubMed ID: 33955541
[TBL] [Abstract][Full Text] [Related]
16. The bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal seizures.
Kahle KT; Staley KJ
Neurosurg Focus; 2008 Sep; 25(3):E22. PubMed ID: 18759624
[TBL] [Abstract][Full Text] [Related]
17. Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective.
Johne M; Römermann K; Hampel P; Gailus B; Theilmann W; Ala-Kurikka T; Kaila K; Löscher W
Epilepsia; 2021 Apr; 62(4):920-934. PubMed ID: 33258158
[TBL] [Abstract][Full Text] [Related]
18. Anomalous levels of Cl- transporters in the hippocampal subiculum from temporal lobe epilepsy patients make GABA excitatory.
Palma E; Amici M; Sobrero F; Spinelli G; Di Angelantonio S; Ragozzino D; Mascia A; Scoppetta C; Esposito V; Miledi R; Eusebi F
Proc Natl Acad Sci U S A; 2006 May; 103(22):8465-8. PubMed ID: 16709666
[TBL] [Abstract][Full Text] [Related]
19. In Vivo Study on Mechanism Underlying Increased Pharmacological Effects of Phenobarbital in Rats with Glycerol-Induced Acute Renal Failure.
Okada A; Suzuki K; Hara K; Kojina M; Aiba T
Biol Pharm Bull; 2019; 42(3):501-506. PubMed ID: 30828081
[TBL] [Abstract][Full Text] [Related]
20. The chloride co-transporters, NKCC1 and KCC2, in experimental autoimmune encephalomyelitis (EAE).
Yousuf MS; Zubkow K; Tenorio G; Kerr B
Neuroscience; 2017 Mar; 344():178-186. PubMed ID: 28057537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
